Full upcoming catalyst calendar

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

601 upcoming events · verified as of 2026-11-05 · soonest first.

All · Readouts · AdComm · Recent approvals

Date	Event	Company	Drug	Official source & verification
2026-11-05 today ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-05 today ESTIMATED	READOUT Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig Phase 2 · B-Cell Malignancies	INCY INCYTE CORP	Parsaclisib, parsaclisib + itacitinib, p	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-05 today ESTIMATED	READOUT A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metast Phase 1/2 · Prostate Cancer	AZN ASTRAZENECA PLC	AZD9750, AZD5305	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-09 in 4d ESTIMATED	READOUT A Platform Study of Novel Immunotherapy Combinations in Participants With Previo Phase 2 · Lung Cancer, Non-Small Cell	GlaxoSmithKline	Pembrolizumab, Dostarlimab, Belrestotug,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-11 in 6d ESTIMATED	READOUT PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast Phase 2 · Cervical Cancer, HPV-Related Carcinoma	PGEN PRECIGEN, INC.	PRGN-2009 plus Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-12 in 7d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-13 in 8d ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-13 in 8d ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar Phase 3 · Breast Cancer	Hoffmann-La Roche	Inavolisib, Fulvestrant, Alpelisib, Bupr	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-13 in 8d ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-14 in 9d ESTIMATED	READOUT A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Di Phase 3 · Type 2 Diabetes Mellitus (T2DM)	BrightGene Bio-Medical Technology	Drug: 5 mg BGM0504 Administered SC, Drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-14 in 9d ESTIMATED	READOUT A Study of BGM0504 in Participants With Type 2 Diabetes Phase 3 · Type 2 Diabetes Mellitus (T2DM)	BrightGene Bio-Medical Technology	Drug: 5 mg BGM0504 Administered SC, Drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-15 in 10d ESTIMATED	READOUT Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis	Primus Pharmaceuticals	Metaxalone 640 mg Oral Tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-15 in 10d ESTIMATED	READOUT Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension	PolyActiva Pty Ltd	PA5108 Ocular Implant low dose, PA5108 O	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-16 in 11d ESTIMATED	READOUT A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	Zilucoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-17 in 12d ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-17 in 12d ESTIMATED	READOUT A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic	Swedish Orphan Biovitrum	Efanesoctocog alfa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-18 in 13d ESTIMATED	READOUT Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym Phase 2/3 · Small Cell Lung Cancer	Han Xu, M.D., Ph.D., FAPCR, Medica	ETOPOSIDE - Usual, ETOPOSIDE - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-18 in 13d ESTIMATED	READOUT Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl Phase 2/3 · Prostate Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Abiraterone - Usual, Abiraterone - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-18 in 13d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-18 in 13d ESTIMATED	READOUT Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Medicine Invention Design, Inc	ALECENSA - alectinib hydrochloride capsu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-18 in 13d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D Phase 2 · Duchenne Muscular Dystrophy	Hoffmann-La Roche	Satralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-18 in 13d ESTIMATED	READOUT An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer Phase 2 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	ToLymph Inc.	SMS001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-19 in 14d ESTIMATED	READOUT A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Par Phase 4 · Severe Hemophilia A, Moderate Hemophilia A	Hoffmann-La Roche	Emicizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-19 in 14d ESTIMATED	READOUT A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participant Phase 2 · Alzheimer's Disease	Hoffmann-La Roche	RO7269162	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-19 in 14d ESTIMATED	READOUT A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatiti Phase 2 · Dermatitis, Atopic	Janssen Research & Development, LL	JNJ-95597528	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-19 in 14d CONFIRMED	ADCOM Microbiology Devices Panel of the Medical Devices Advisory Committee Microbiology Devices Panel of the Medical Devices Advisory Committee	Microbiology Devices Panel of the	FDORA	Federal Register (FDA notice) ↗ ✓ Source-checked 2026-11-05 Scheduled FDA meeting date
2026-11-20 in 15d ESTIMATED	READOUT Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With Phase 3 · Endometrial Neoplasms	Merck Sharp & Dohme LLC	Pembrolizumab, Carboplatin, Paclitaxel,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-20 in 15d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 2 · Moderate to Severe Asthma	INCY INCYTE CORP	povorcitinib, ICS-LABA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-20 in 15d ESTIMATED	READOUT Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-admi Phase 2 · Obesity	SKYE Skye Bioscience, Inc.	Nimacimab injection, Nimacimab placebo i	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-23 in 18d ESTIMATED	READOUT A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) V Phase 2 · Neoplasms, Colon	GlaxoSmithKline	Dostarlimab, CAPEOX	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-23 in 18d ESTIMATED	READOUT A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to He Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine, Marke	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-24 in 19d ESTIMATED	READOUT Avelumab Program Rollover Study Phase 3 · Solid Tumors	EMD Serono Research & Development	Avelumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-24 in 19d ESTIMATED	READOUT Study of AZD0754 in Participants With Metastatic Prostate Cancer Phase 1/2 · Metastatic Prostate Cancer	AZN ASTRAZENECA PLC	AZD0754, AZD2287	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-24 in 19d ESTIMATED	READOUT A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer Phase 3 · Alzheimer Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-24 in 19d ESTIMATED	READOUT A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart F Phase 2 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction	TECX Tectonic Therapeutic, Inc.	TX000045- Dose A, TX000045- Dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-26 in 21d ESTIMATED	READOUT A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Phase 3 · Neoplasms	Tesaro, Inc.	Dostarlimab, Carboplatin, Paclitaxel, Ni	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-26 in 21d ESTIMATED	READOUT Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and Phase 4 · COVID-19	SNY Sanofi	Omicron Subvariant-Based SARS-CoV-2 Reco	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-28 in 23d ESTIMATED	READOUT A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Phase 2 · Parkinson's Disease (PD)	TrueBinding, Inc.	TB006	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-28 in 23d ESTIMATED	READOUT A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P Phase 3 · Yellow Fever Immunization	SNY Sanofi	Yellow fever vaccine (live), Yellow feve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-29 in 24d ESTIMATED	READOUT A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f Phase 3 · Menstrual Migraine	PFE PFIZER INC	Rimegepant, Rimegepant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutat Phase 1/2 · Glioblastoma Multiforme	NTHI NEONC TECHNOLOGIES HOLDINGS,	Perillyl alcohol	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-L Phase 3 · Cancer	Hoffmann-La Roche	Atezolizumab, Bevacizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Microdystrophin Gene Transfer Study in Adolescents and Children With DMD Phase 1/2 · Duchenne Muscular Dystrophy	SLDB Solid Biosciences Inc.	SGT-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety Phase 1/2 · Multiple Myeloma	Celgene	CC-92480, Bortezomib, Dexamethasone, Dar	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Phase 2 · Non-small Cell Lung Cancer	Genentech, Inc.	Alectinib, Entrectinib, Vemurafenib, Cob	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT Phase 1/2 · Advanced MTAP-null Solid Tumors	AMGN AMGEN INC	Anvumetostat, Docetaxel, Comparator Anvu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage D Phase 1/2 · Glycogen Storage Disease	ModernaTX, Inc.	mRNA-3745	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Pediatric Patients Aged 4 to 11 Years With APDS Phase 3 · APDS	Pharming Technologies B.V.	Leniolisib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte A Phase 3 · Leukocyte Adhesion Deficiency	AUG Therapeutics	AVTX-803 (L-Fucose)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Phase 1/2 · Metastatic Castration-resistant Prostate Cancer	OncoC4, Inc.	ONC-392 low, ONC-392 high, lutetium Lu 1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Phase 1/2 · Mesial Temporal Lobe Epilepsy	UniQure Biopharma B.V.	AAV9-hSyn1-miGRIK2	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Suprachoroidal Administration in Subjects With Metastases to the Choroid Phase 2 · Eye Cancer, Primary Cancer	AURA Aura Biosciences, Inc.	AU-011, SCS Microinjector, Laser	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study of TAK-360 in Adults With Idiopathic Hypersomnia Phase 2 · Idiopathic Hypersomnia	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) Phase 2 · Narcolepsy Type 2	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metast Phase 3 · Breast Cancer	InventisBio Co., Ltd	D-0502, Fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12 Phase 1/2 · KRAS G12D Mutation, Advanced Solid Cancer	ARVN ARVINAS, INC.	ARV-806	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production C Phase 2 · Monkeypox (Mpox)	Bavarian Nordic	Jynneos, MVA-BN (Quail)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha Phase 3 · Immune Thrombocytopenia	SNY Sanofi	rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis K Phase 3 · Osteoarthritis Knee Pain	Saol Therapeutics Inc	SL1002, Normal Saline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Investigating Ovulation Inhibition for Use as a Contraceptive Phase 2 · Contraception	Mylan Pharmaceuticals Inc	MR-130A-01 contraceptive transdermal pat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE Phase 2 · Obesity and Cardiovascular Risk	BIOA BioAge Labs, Inc.	Oral BGE-102, Oral Placebo Matching BGE-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-11-30 in 25d ESTIMATED	READOUT Study to Assess Safety and Tolerability of KarXT With Administration of Antiemet Phase 4 · Healthy Volunteers	Karuna Therapeutics, Inc., a Brist	KarXT, Trimethobenzamide, Ondansetron, M	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Ly Phase 2 · Diffuse Large B-cell Lymphoma	KPTI Karyopharm Therapeutics Inc.	Selinexor, Selinexor, Selinexor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers Phase 1/2 · Colorectal Cancer, Pancreatic Cancer	Lumicell, Inc.	LUM015, LUM 2.6 Imaging Device	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer Phase 1/2 · Cancer, Neoplasms	Cancer Vaccines Limited	ACIT-1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patie Phase 2 · Cushing Syndrome	CORT CORCEPT THERAPEUTICS INC	relacorilant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects Wi Phase 3 · PAH, Pulmonary Hypertension	UTHR UNITED THERAPEUTICS Corp	Ralinepag	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Study of Apalutamide in Participants With High-Risk, Localized or Locally Adva Phase 3 · Prostatic Neoplasms	Janssen Research & Development, LL	Apalutamide, Androgen Deprivation Therap	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stab Phase 3 · Chronic Stable Angina Pectoris	Tasly Pharmaceuticals, Inc.	T89 capsule	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Mus Phase 2 · Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG	TLTFF THERALASE TECHNOLOGIES INC /	Ruvidar® (TLD-1433) bladder infusion and	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) Phase 2 · Lumbar Disc Disease	BRTX BioRestorative Therapies, In	BRTX-100, Saline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer Phase 1/2 · Metastatic Breast Cancer	Phoenix Molecular Designs	PMD-026, fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Exten Phase 4 · Ulcerative Colitis	BHC Bausch Health Companies Inc.	Low Dose Budesonide, High Dose Budesonid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Phase 2/3 · Relapsed/Refractory Diffuse Large B-cell Lymphoma	KPTI Karyopharm Therapeutics Inc.	Selinexor (combination therapy), Selinex	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumor Phase 2 · Solid Tumor	Intra-IMMUSG Pte Ltd	PRL3-zumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Phase 1/2 · Glioblastoma, Melanoma Stage IV	Sapience Therapeutics	ST101, Temozolomide, Radiation	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation Phase 1/2 · Dry Age-related Macular Degeneration	Luxa Biotechnology, LLC	RPESC-RPE-4W	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2 · Solid Tumor, Adult, Cancer	EpicentRx, Inc.	AdAPT-001, Checkpoint Inhibitor, Immune	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere Phase 2/3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314, ABBV-RGX-314, Ranibizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) Phase 2 · HER2 Positive Metastatic Breast Cancer	Ambrx, Inc.	ARX788	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergo Phase 3 · Congenital Antithrombin Deficiency	Octapharma	Atenativ	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Ped Phase 3 · Primary Immunodeficiency Disease	Kedrion S.p.A.	Kedrion IVIG 10%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castrat Phase 2 · Metastatic Castration-Resistant Prostate Cancer	Zenith Epigenetics	ZEN003694, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/3 · Acute Stroke, Ischemic Stroke	DMAC DiaMedica Therapeutics Inc.	Recombinant human tissue kallikrein	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Se Phase 2 · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	K-Group, Beta, Inc., a wholly owne	azenosertib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Cap Phase 2 · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)	Sunshine Lake Pharma Co., Ltd.	HEC585 dose A, HEC585 dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractor Phase 1/2 · Refractory Metastatic Colorectal Cancer, Solid Tumor	Rottapharm Biotech	CR6086, AGEN2034	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyna Phase 1/2 · Frontotemporal Dementia	DNLI Denali Therapeutics Inc.	DNL593	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Phy Phase 3 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer	GNLX GENELUX Corp	olvimulogene nanivacirepvec, Platinum ch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety and Efficacy of APG-157 in Head and Neck Cancer Phase 2 · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity	Aveta Biomics, Inc.	APG-157	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due t Phase 1/2 · Breast Neoplasms, Brain Neoplasms	Stemline Therapeutics, Inc.	Elacestrant, Abemaciclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Proph Phase 3 · Hereditary Angioedema	IONS IONIS PHARMACEUTICALS INC	Donidalorsen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (i Phase 2 · Multiple Myeloma	Kite, A Gilead Company	anitocabtagene-autoleucel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Phase 3 · Agitation, Alzheimer's Type Dementia	Suven Life Sciences Limited	Masupirdine 50 mg, Masupirdine 100 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K A Phase 1/2 · HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer	SynDevRx, Inc.	Evexomostat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Phase 2 · Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung	LTRN Lantern Pharma Inc.	LP-300, Pemetrexed, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refra Phase 1/2 · Lymphoma, B-Cell, Lymphoma, T-Cell	Step Pharma, SAS	STP938	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP Phase 1/2 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)	AP Biosciences Inc.	AP203, AP203	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotox Phase 1/2 · LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma	Dren Bio	DR-01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated Phase 3 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor	RayzeBio, Inc.	RYZ101, Everolimus, Sunitinib, Octreotid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pat Phase 3 · NASH, Cirrhosis, Liver	MDGL MADRIGAL PHARMACEUTICALS, IN	Resmetirom	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Alloge Phase 1/2 · Glioblastoma	INAB IN8BIO, INC.	Autologous genetically modified gamma-de	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of AMDX-2011P in Participants With CAA Phase 2 · Cerebral Amyloid Angiopathy	Amydis Inc.	AMDX-2011P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fus Phase 2 · Advanced Cholangiocarcinoma, FGFR2 Fusions	Taiho Oncology, Inc.	TAS-120	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in P Phase 1/2 · Solid Tumor, Adult, Solid Tumor	A2 Biotherapeutics Inc.	A2B530, xT-Onco with HLA-LOH Assay	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes Phase 2 · Type 1 Diabetes Mellitus With Hypoglycemia	Zucara Therapeutics Inc.	ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Ob Phase 3 · Fecal Incontinence	Cook MyoSite	Iltamiocel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Phase 2 · Hypoxic-Ischemic Encephalopathy	ReAlta Life Sciences, Inc.	RLS-0071	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Ad Phase 1/2 · Solid Tumor, Biliary Tract Cancer	TiumBio Co., Ltd.	TU2218 + KEYTRUDA® (Pembrolizumab)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease Phase 1/2 · Neuronal Ceroid Lipofuscinosis Type 2	Tern Therapeutics, LLC	TTX-381, TTX-381	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Phase 2 · Lymphatic Malformation	TARA Protara Therapeutics, Inc.	TARA-002	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T- Phase 1/2 · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma	BEAM Beam Therapeutics Inc.	BEAM-201	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of ALTO-300 in MDD Phase 2 · Major Depressive Disorder	ANRO Alto Neuroscience, Inc.	ALTO-300	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchym Phase 1/2 · Heart Failure, Systolic	BCDA BioCardia, Inc.	CardiALLO™ Human Allogenic Culture-expan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-a Phase 3 · Cholangiocarcinoma	TransThera Sciences (Nanjing), Inc	Tinengotinib 8 mg, Tinengotinib 10 mg, P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced o Phase 2 · Endometrial Cancer, Endometrioid Tumor	Aadi Bioscience, Inc.	nab-sirolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT Descartes-08 for Patients With Systemic Lupus Erythematosus Phase 2 · Systemic Lupus Erythematosus (SLE)	RNAC Cartesian Therapeutics, Inc.	Descartes-08	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophi Phase 2 · Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome	NS Pharma, Inc.	NS-229	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of BN104 in the Treatment of Acute Leukemia Phase 1/2 · ALL, Adult, AML, Adult	Institut de Recherches Internation	BN104 monotherapy, BN104 monotherapy, BN	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squ Phase 2 · Vulvar Diseases, HPV Infection	Frantz Viral Therapeutics, LLC	Artesunate ointment	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Part Phase 2 · Acute Pancreatitis	Panafina, Inc.	RABI-767	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis Phase 1/2 · Light Chain (AL) Amyloidosis	Nexcella Inc.	NXC-201 CAR-T	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity in Previously Trea Phase 2 · Unresectable Metastatic Colorectal Cancer	ABBV AbbVie Inc.	ABBV-400, Bevacizumab, Folinic Acid, Flu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Gene Therapy for ACM Due to a PKP2 Pathogenic Variant Phase 1/2 · Arrhythmogenic Cardiomyopathy, PKP2-ACM	LXEO Lexeo Therapeutics, Inc.	LX2020	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Phase 2/3 · Focal Epilepsy	BHVN Biohaven Ltd.	BHV-7000, BHV-7000, BHV-7000	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamic Phase 1/2 · Solid Tumor	Alyssum Therapeutics	AT-1965 Liposome Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patie Phase 2 · NSCLC	EIKN Eikon Therapeutics, Inc.	EIK1001, Pembrolizumab, Paclitaxel, Peme	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate C Phase 1/2 · MRI Scan	Songqi Gao	MT218 injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT ZILRETTA in Subjects With Shoulder Osteoarthritis Phase 3 · Glenohumeral Osteoarthritis	PCRX Pacira BioSciences, Inc.	ZILRETTA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EX Phase 3 · Pulmonary Arterial Hypertension	Gossamer Bio USA, Inc.	Seralutinib, Gereic Dry Powder Inhaler	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumo Phase 1/2 · Advanced Solid Tumor	Latticon Antibody Therapeutics, In	LAT010, LAT010 + ICI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) Phase 2 · Pressure Ulcer, Stage IV, Osteomyelitis	Biocomposites Ltd	STIMULAN VG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal He Phase 2 · Paroxysmal Nocturnal Hemoglobinuria	OMER OMEROS CORP	OMS906 study drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Phase 2 Study of WGI-0301 for Advanced HCC Phase 2 · Advanced Hepatocellular Carcinoma (HCC)	Zhejiang Haichang Biotech Co., Ltd	WGI-0301 at MTD/RP2D dose IV infusion, Q	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT SPI-1005 in Adults Receiving Cochlear Implant Phase 2 · Hearing Loss, Cochlear Trauma	Sound Pharmaceuticals, Incorporate	Ebselen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalize Phase 2 · Steroid Refractory GVHD	ReAlta Life Sciences, Inc.	RLS-0071	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients W Phase 3 · Acute Hereditary Angio Edema	Octapharma	OCTA-C1-INH	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Phase 1/2 · Advanced or Metastatic Solid Tumors, Breast Cancer	858 Therapeutics, Inc.	ETX-19477	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With o Phase 2 · Acute Ischemic Stroke	NoNO Inc.	NoNO-42	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Phase 3 · Binge-Eating Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 150 mg, Solriamfetol 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Phase 2 · Myasthenia Gravis, Myasthenia Gravis, MuSK	NMD Pharma A/S	NMD670	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) Phase 2 · Basal Cell Carcinoma	Highlight Therapeutics	BO-112	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors Phase 1/2 · Melanoma Stage IV, Solid Tumor	Georgiamune Inc	GIM-531, Anti-PD-1 monoclonal antibody	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Long-term Safety and Tolerability of BHV-7000 Phase 2 · Focal Epilepsy	BHVN Biohaven Ltd.	BHV-7000, BHV-7000	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Phase 2 · Moderately to Severely Active Crohn Disease	ABVX Abivax S.A.	Obefazimod	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adoles Phase 3 · Hidradenitis Suppurativa	ABBV AbbVie Inc.	Lutikizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Phase 2 · Multifocal Motor Neuropathy	DNTH Dianthus Therapeutics, Inc.	Claseprubart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shif Phase 3 · Excessive Sleepiness, Shift-work Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 150 mg, Solriamfetol 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Double Blind Study Performed to Evaluate the Efficacy and the Safety of Eschar Phase 3 · Venous Leg Ulcer (VLU)	MDWD MediWound Ltd.	EscharEx (EX-03)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone Mas Phase 2 · Postmenopausal Osteoporosis	Angitia Biopharmaceuticals	AGA2118	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Phase 1/2 · Solid Tumor	Lamassu Bio Inc	SA53-OS (phase 1), SA53-OS (phase 2)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control Phase 2 · Myopia, Progressive	Sunhawk Vision Biotech, Inc.	SHJ002, Atropine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Phase 3 · Eosinophilic Esophagitis	Dr. Falk Pharma GmbH	Budesonide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given D Phase 2 · Refractory Metastatic Colorectal Cancer	DCTH DELCATH SYSTEMS, INC.	Melphalan/HDS Followed by Consolidation	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten R Phase 1/2 · KRAS G12D Mutation	Ranok Therapeutics (Hangzhou) Co.,	RNK08954-01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Study to Learn More About the Effects and Safety of Felzartamab Infusions in A Phase 3 · Antibody-mediated Rejection	BIIB BIOGEN INC.	Felzartamab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Tissue Repair Gel in Venous Leg Ulcers in AU/US Phase 3 · Venous Leg Ulcer, Venous Ulcer	TR Therapeutics	TR987 0.1% gel + Standard of Care	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Phase 2/3 · Microvillus Inclusion Disease, Congenital Disorders	Napo Pharmaceuticals, Inc.	Crofelemer Powder for Oral Solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Phase 2 · Narcolepsy Type 1, Narcolepsy Type 2	Centessa Pharmaceuticals (UK) Limi	ORX750	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Wit Phase 1/2 · Type 1 Diabetes Mellitus, T1D	COUR Pharmaceutical Development Co	CNP-103	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Phase 3 · Pneumococcal Infections	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT Spermatogonial Differentiation Via Testicular Organoid Phase 1/2 · Infertility, Male, Gene Abnormality	CellARTs Inc.	Stem cell, Genetic Screening, Genetic Re	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of Navenibart in Participants With Hereditary Angioedema Phase 3 · Hereditary Angioedema (HAE)	Astria Therapeutics, Inc.	navenibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Phase 2 · Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy	DWTX Dogwood Therapeutics, Inc.	Halneuron, Halneuron (Open Label Extensi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Phase 1/2 · oGHVD	Regenerative Ocular Immunobiologic	d-MAPPS, PI and Patient Masked	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT SPI-1005 for the Treatment of Meniere's Disease (Open Label) Phase 3 · Meniere's Disease, Ménière's Disease	Sound Pharmaceuticals, Incorporate	Ebselen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT Study to Evaluate the Safety and the Immunogenicity of a Second Generation Struc Phase 1/2 · Pandemic Influenza Immunization, Healthy Volunteers	SNY Sanofi	Pandemic flu H5 HA mRNA SD2 vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retini Phase 2 · Retinitis Pigmentosa	jCyte, Inc	human retinal progenitor cells, Mock inj	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety and Efficacy of VDPHL01 in Males With AGA Phase 3 · Androgenetic Alopecia, AGA	MANE Veradermics, Inc	VDPHL01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Phase 1/2 · Neurotrophic Keratitis	KRYS Krystal Biotech, Inc.	KB801	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerabil Phase 3 · Developmental and Epileptic Encephalopathy 1	PRAX Praxis Precision Medicines,	1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermo Phase 3 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa	KRYS Krystal Biotech, Inc.	KB803	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Saf Phase 3 · Epileptic Encephalopathy, SCN2A Encephalopathy	PRAX Praxis Precision Medicines,	1mg elsunersen, 0.5mg elsunersen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Sy Phase 2 · Non-obstructive Hypertrophic Cardiomyopathy	Imbria Pharmaceuticals, Inc.	Ninerafaxstat 200mg MR	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Phase 3 · Chronic Primary Immune Thrombocytopenia (ITP)	Kedrion S.p.A.	Kedrion IVIG 10%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemoli Phase 2 · Chronic Pruritus of Unknown Origin	Galderma R&D	nemolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infect Phase 3 · Viral Hepatitis	VIR Vir Biotechnology, Inc.	Tobevibart, Elebsiran, Bulevirtide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease ( Phase 1/2 · Parkinson's Disease (PD)	EicOsis Human Health Inc.	EC5026 oral tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Phase 2 · Nausea, Vomiting	LLY ELI LILLY & Co	LY3537021, Background Chemotherapy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifung Phase 2 · Invasive Mould Infection	Elion Therapeutics, Inc.	EL219, Active Comparator- IV Antifungal	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment Phase 3 · Social Anxiety Disorder (SAD)	VNDA Vanda Pharmaceuticals Inc.	VQW-765	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With Phase 2 · Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus	Ventus Therapeutics U.S., Inc.	VENT-03	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Phase 2 · Atopic Dermatitis (AD)	Enveda Therapeutics	ENV-294	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults Phase 2 · Asthma	Enveda Therapeutics	ENV-294	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD Phase 2 · Pulmonary Hypertension, Interstitial Lung Disease (ILD)	Pulmovant, Inc.	inhaled mosliciguat, Dry Powder Inhaler	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma Phase 3 · Primary Vitreoretinal Lymphoma	ALDX Aldeyra Therapeutics, Inc.	ICM ADX-2191 injection, Monthly ADX-2191	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-01 in 26d ESTIMATED	READOUT A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1 Phase 3 · Nausea and Vomiting, Obesity	VNDA Vanda Pharmaceuticals Inc.	Tradipitant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Partici Phase 2 · RSV Infection, RSV	ENTA ENANTA PHARMACEUTICALS INC	zelicapavir	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Canc Phase 3 · Lung Cancer, Lung Metastases	Vergent Bioscience, Inc.	Abenacianine, Near Infrared (NIR) Imagin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospit Phase 2 · Hypertension, Acute Severe Hypertension	KARD Kardigan, Inc.	Tonlamarsen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL Phase 1/2 · Bipolar I Disorder	ALZN Alzamend Neuro, Inc.	AL001, Lithium carbonate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Clinical Study Evaluating Licaminlimab for Dry Eye Disease Phase 2/3 · Dry Eye Disease (DED)	OCS Oculis Holding AG	Artificial Tear Run-in, licaminlimab, Ve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT Rademikibart IV for Acute Asthma and COPD Exacerbation Phase 2 · Asthma Acute, COPD Exacerbation Acute	Connect Biopharm LLC	Rademikibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12 (month) in 26d ESTIMATED	READOUT A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Sus Phase 3 · Postoperative Ocular Inflammation, Postoperative Ocular Pain	HROW HARROW, INC.	TRIESENCE (triamcinolone acetonide injec	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-02 in 27d ESTIMATED	READOUT A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t Phase 3 · Severe Alopecia Areata	PFE PFIZER INC	Ritlecitinib higher dose, Ritlecitinib l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-03 in 28d ESTIMATED	READOUT A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)	REGN REGENERON PHARMACEUTICALS, I	REGN7999	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-03 in 28d ESTIMATED	READOUT A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Phase 2 · Alzheimer's Disease	Eisai Inc.	E2814, Lecanemab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-04 in 29d ESTIMATED	READOUT A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D Phase 3 · Lyme Disease	PFE PFIZER INC	VLA15	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-08 in 1mo ESTIMATED	READOUT A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation Phase 3 · Atrial Fibrillation	Janssen Research & Development, LL	Milvexian, Apixaban, Apixaban Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-08 in 1mo ESTIMATED	READOUT A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults Phase 2 · Hidradenitis Suppurativa	PFE PFIZER INC	Ritlecitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-09 in 1mo ESTIMATED	READOUT A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As Phase 3 · Psychosis Associated With Alzheimer's Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-10 in 1mo ESTIMATED	READOUT Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People Wi Phase 3 · Lung Cancer, Non-squamous, Non-small Cell	Boehringer Ingelheim	zongertinib, pembrolizumab, cisplatin, c	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-10 in 1mo ESTIMATED	READOUT A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Ba Phase 2 · Chronic Kidney Disease and Hypertension	AZN ASTRAZENECA PLC	Baxdrostat/dapagliflozin, Baxdrostat/Pla	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-11 in 1mo ESTIMATED	READOUT Extended Access of Momelotinib in Adults With Myelofibrosis Phase 2 · Primary Myelofibrosis	GlaxoSmithKline	Momelotinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-11 in 1mo ESTIMATED	READOUT A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th Phase 2 · Urothelial Carcinoma	Seagen, a wholly owned subsidiary	disitamab vedotin, pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-11 in 1mo ESTIMATED	READOUT A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-co Phase 4 · SARS-CoV-2	ModernaTX, Inc.	mRNA-1273, mRNA-1283	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moder Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, 68Ga-PSMA-11	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Phase 2 · Heart Failure	BMY BRISTOL MYERS SQUIBB CO	BMS-986435	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)	AMGN AMGEN INC	ABP 234, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT A Study on the Immune Response and Safety of the Second Dose of an Investigation Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine, Marke	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 Phase 2 · Palmoplantar Pustulosis	LEO Pharma	Delgocitinib cream, Vehicle cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help P Phase 2 · Overweight, Obesity	NVO NOVO NORDISK A S	NNC0662-0419	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants ( Phase 3 · Schizophrenia	Gedeon Richter Plc.	Cariprazine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5 Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm	PMVP PMV Pharmaceuticals, Inc.	rezatapopt, pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory De Phase 2/3 · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Janssen Research & Development, LL	Nipocalimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab Phase 1/2 · Solid Tumor, Adult, Refractory Cancer	GV20 Therapeutics	GV20-0251, GV20-0251, GV20-0251 and Pemb	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Phase 3 · Non-Clear Cell Renal Cell Carcinoma	EXEL EXELIXIS, INC.	XL092, Nivolumab, Sunitinib Malate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With ACh Phase 3 · Generalized Myasthenia Gravis, gMG	Alexion Pharmaceuticals, Inc.	Gefurulimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Ad Phase 2 · Locally Advanced Pancreatic Adenocarcinoma	EXACT Therapeutics AS	Acoustic Cluster Therapy, Modified FOLFI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Modera Phase 3 · Moderate to Severe Glabellar Lines	Ipsen	Corabotase	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-15 in 1mo ESTIMATED	READOUT A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults W Phase 3 · Moderate to Severe Glabellar Lines	Ipsen	Corabotase	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-16 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodyn Phase 3 · NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis	Hoffmann-La Roche	Satralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-16 in 1mo ESTIMATED	READOUT A Clinical Investigation of a Topical Moisturizer on Skin Barrier Function in Ad Phase 4 · Sensitive Skin	Good Molecules, LLC	White petrolatum, Investigational moistu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Mon Phase 2 · Alzheimer Disease, Early Onset	BMY BRISTOL MYERS SQUIBB CO	BMS-986446	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Cr Phase 2 · Crohn's Disease	SNY Sanofi	brivekimig	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participan Phase 2 · Ulcerative Colitis	SNY Sanofi	SAR442970	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-861	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-18 in 1mo ESTIMATED	READOUT Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymo Phase 2/3 · Breast Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Raloxifene - Usual, Raloxifene - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-18 in 1mo ESTIMATED	READOUT Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polym Phase 2/3 · SCLC	Han Xu, M.D., Ph.D., FAPCR, Medica	Topotecan - usual, Topotecan - study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-21 in 2mo ESTIMATED	READOUT A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Phase 3 · Hidradenitis Suppurativa	UCB Biopharma SRL	Bimekizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-22 in 2mo ESTIMATED	READOUT A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa Phase 1/2 · Renal Cell Carcinoma	Merck Sharp & Dohme LLC	Belzutifan, Palbociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-22 in 2mo ESTIMATED	READOUT A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease Phase 2 · Alzheimer Disease	Janssen Pharmaceutica N.V., Belgiu	JNJ-64042056	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-22 in 2mo ESTIMATED	READOUT A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Phase 2 · Geographic Atrophy	Boehringer Ingelheim	BI 1584862	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-22 in 2mo ESTIMATED	READOUT Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants Phase 3 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD	Adverum Biotechnologies, Inc.	Ixo-vec, Aflibercept	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Tim Phase 3 · Asthma	AZN ASTRAZENECA PLC	Benralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients Phase 2 · Prostatic Neoplasm	NVS NOVARTIS AG	AAA617, AAA517, Piflufolastat F 18, ARPI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Phase 1/2 · Non-Hodgkin Lymphoma	Cho Pharma Inc.	CHO-H01, CHO-H01 at RP2D, Lenalidomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration- Phase 2 · Metastatic Castration-resistant Prostate Cancer	Fusion Pharmaceuticals Inc.	FPI-2265	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-23 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab Phase 2 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion	SNY Sanofi	frexalimab, brivekimig, rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-25 in 2mo ESTIMATED	READOUT A Study on the Immune Response and Safety of an Investigational Chickenpox Vacci Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine_Lot 1,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-25 in 2mo ESTIMATED	READOUT A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont Phase 2 · Chronic Spontaneous Urticaria	PFE PFIZER INC	Ritlecitinib 50 mg, Ritlecitinib 100 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-26 in 2mo ESTIMATED	READOUT Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovari Phase 3 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms	CanariaBio Inc.	Oregovomab, Paclitaxel, Carboplatin, Car	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-26 in 2mo ESTIMATED	READOUT A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Partici Phase 3 · Hidradenitis Suppurativa (HS)	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-27 in 2mo ESTIMATED	READOUT Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Vari Phase 1/2 · Breast Cancer, Metastatic Breast Cancer	Stemline Therapeutics, Inc.	Elacestrant, Alpelisib, Everolimus, Ribo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-27 in 2mo ESTIMATED	READOUT An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Phase 2 · Dry Eye Disease (DED)	Dompé Farmaceutici S.p.A	DFL24498, Vehicle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-27 in 2mo ESTIMATED	READOUT Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients Wit Phase 2 · High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion	Amplexd Therapeutics, Inc.	EGCG and Quinine Sulfate Vaginal Supposi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-28 in 2mo ESTIMATED	READOUT A Long-term Treatment Extension Study of Niraparib in Participants Who Completed Phase 2 · Ovarian Neoplasms, Breast Neoplasms	GlaxoSmithKline	Niraparib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-28 in 2mo ESTIMATED	READOUT Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-a Phase 2 · Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition	Frantz Viral Therapeutics, LLC	Artesunate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-29 in 2mo ESTIMATED	READOUT A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult P Phase 2 · Hypercholesterolemia	REGN REGENERON PHARMACEUTICALS, I	Alirocumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change
2026-12-30 in 2mo ESTIMATED	READOUT Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients Phase 3 · Tuberous Sclerosis Complex	NVS NOVARTIS AG	everolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-05 Sponsor-projected date — can change